Welcome, Guest
Username: Password: Remember me

TOPIC: TBUFF (Mcap $19 M) 7 Drugs launched & 1 Potential Blockbuster close to Market =10 BAGGER Potential !

6 years 3 weeks ago #3712

Breakout to new 52W high is imminent ...GLTA


Bezalip alone is worth more than $3 per Share ...
Significant Potential of Bezalip SR® in U.S.Market
Tribute has licensed the exclusive rights to Bezalip SR, a drug that lowers cholesterol and triglycerides, in the U.S. and Canada.Tribute now sells Bezalip SR in Canada and is developing its strategy to obtain FDA approval in the U.S., addressing the $3 billion U.S.fibrate market, a subset of the $20 billion U.S. and Canadian dyslipidemia market. Tribute recognizes Bezalip SR in the U.S as a significant asset and seeks to maximize this opportunity.Bezalip SR is approved in more than 40 countries worldwide.

Bezalip® SR USA

Tribute will seek and FDA approval for Bezalip SR in the US

Tributewill leverage data from the Canadian file with it’s FDA submission

One additional US based phase III study will be required to file

Tribute met with the FDA in March 2012 to discuss the filing strategy for the US

Tribute plans to file an IND with the FDA before the end of the year 2013

Tribute will likely look for a partner to commercialize Bezalip SR in the US
The administrator has disabled public write access.

TBUFF (Mcap $19 M) 7 Drugs launched & 1 Potential Blockbuster close to Market =10 BAGGER Potential ! 6 years 1 month ago #3694

A MEGA Lifetime Opportunity here

This Undiscovered and Low Float Goldmine is BRUTALLY Underpriced . They have already 7 Drugs on the Market and 1 Potential Blockbuster(Bezalip SR®) close to enter the US Market .
The Annual Revenue hits $13 Mil in last year almost similar to Antares Pharma (ATRS) which has a Market Cap of $570 M .

The Market Cap of $19 M is really a Big Joke and thats why the Insider buying like hell please see the link below .
This Stock should trade over $5 per Share instead of $0.40 . This is your Opp to get in very very Cheap before this Goldmine gets discovered .GLTA


Ticker: TBUFF

Market Cap: $19.7M
Shares Out: 51.0M
Fully Diluted Shares: 68.5M

Insider Ownership: 56.7%


BRUTAL Insider Buying
http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions


Presentation May 2013
http://content.stockpr.com/tributepharma/media/0a26f60f9fe2b220d091c62d6123d81e.pdf


Fact Sheet--MUST READ
http://content.stockpr.com/tributepharma/media/cceaf7664429c13e4f2159e8abf81c60.pdf

Specialty Pharma with High Growth,Low Risk Business Model
Tribute primarily licenses products that have already
progressed through significant R&D investment and
in many cases,already received regulatory approval
in Canada or other countries. To date,Tributehas
developed or in -licensed 8 products,7 of which
the Company is currently selling.The Company does not invest heavily in R&D, but rather looks tobenefit after the
R&D risk is mitigated.

Growing Revenues
The Company, formerly known as Stellar Pharmaceuticals,
completed its acquisition of privately held Tribute Pharmaceuticals in December of 2011 and changed its name to Tribute in January 2013. Gross revenues havegrown to $13.1
million for the 12 months ended September 30, 2012 when including
revenues of both companies for the last four quarters. In October of 2012 Tribute launched a key new product, CAMBIA®, for the treatment of migraine headaches, which addresses a $150 million market in Canada and is expected to make a meaningful contribution to revenues in Q4 and beyond.The Company is actively looking to build out its product portfolio to generate additional near term revenues.

Established Sales Infrastructure in Canadian Market
Canada is the 10th largest healthcare market in the
world, driven by its national healthcare plan which covers 100% of its population. It’s a geographic market served by very few specialty pharmaceutical companies.With 24 full time sales people,
Tribute sells and distributes to doctors,hospitals and clinics through out Canada. Leveraging its sales and distribution infrastructure,Tribute negotiates for the exclusive license to sell products developed by companies like Pfizer in the Canadian market.

Significant Potential of Bezalip SR® in U.S.Market
Tribute has licensed the exclusive rights to Bezalip SR,
a drug that lowers cholesterol and triglycerides, in the U.S. and Canada.Tribute now sells Bezalip SR in Canada and is developing
its strategy to obtain FDA approval in the U.S.
, addressing the $3 billion U.S.fibrate market, a subset of
the $20 billion U.S. and Canadian dyslipidemia market
.Tribute recognizes Bezalip SR in the U.S as a significant asset and seeks to maximize this opportunity.Bezalip SR is approved in more than 40 countries worldwide.

Accomplished Management Team
Tribute’s management team and board members have
successfully built pharmaceutical companies that have been subsequently sold for valuations over $3 billion. Their industry relationships, expertise in licensing
and building sales forces are key value drivers for the Company.
The administrator has disabled public write access.